WO2023150601A3 - Multi-cyclic irak and flt3 inhibiting compounds and uses thereof - Google Patents

Multi-cyclic irak and flt3 inhibiting compounds and uses thereof Download PDF

Info

Publication number
WO2023150601A3
WO2023150601A3 PCT/US2023/061824 US2023061824W WO2023150601A3 WO 2023150601 A3 WO2023150601 A3 WO 2023150601A3 US 2023061824 W US2023061824 W US 2023061824W WO 2023150601 A3 WO2023150601 A3 WO 2023150601A3
Authority
WO
WIPO (PCT)
Prior art keywords
flt3
irak
compounds
compositions
inhibiting compounds
Prior art date
Application number
PCT/US2023/061824
Other languages
French (fr)
Other versions
WO2023150601A2 (en
Inventor
Scott Bryan HOYT
Craig Joseph THOMAS
Gregory J. TAWA
Jan Susan Rosenbaum
Gabriel GRACIA MALDONADO
Daniel T. STARCZYNOWSKI
Original Assignee
Children's Hospital Medical Center
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Kurome Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital Medical Center, The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Kurome Therapeutics, Inc. filed Critical Children's Hospital Medical Center
Publication of WO2023150601A2 publication Critical patent/WO2023150601A2/en
Publication of WO2023150601A3 publication Critical patent/WO2023150601A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the disclosed compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
PCT/US2023/061824 2022-02-02 2023-02-02 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof WO2023150601A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263305834P 2022-02-02 2022-02-02
US63/305,834 2022-02-02
US202263355318P 2022-06-24 2022-06-24
US63/355,318 2022-06-24

Publications (2)

Publication Number Publication Date
WO2023150601A2 WO2023150601A2 (en) 2023-08-10
WO2023150601A3 true WO2023150601A3 (en) 2023-09-28

Family

ID=87553006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/061824 WO2023150601A2 (en) 2022-02-02 2023-02-02 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2023150601A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of flt3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200199123A1 (en) * 2016-08-17 2020-06-25 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200199123A1 (en) * 2016-08-17 2020-06-25 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUCKLEY ET AL.: "IRAK -4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 18, 2008, pages 3656 - 3660, XP022707452, DOI: 10.1016/j.bmcl.2008.04.042 *
MELGAR ET AL.: "Overcoming adaptive therapy resistance in AML by targeting immune response pathways", SCI TRANSL MED., vol. 11, no. 508, 2019, pages 33, XP093030847, DOI: 10.1126/scitranslmed.aaw8828 *
NACCACHE ET AL.: "Patterns of Nonelectrolyte Permeability in Human Red Blood Cell Membrane", JOURNAL OF GENERAL PHYSIOLOGY, vol. 62, 1973, pages 714 - 736, XP093070908, DOI: 10.1085/jgp.62.6.714 *

Also Published As

Publication number Publication date
WO2023150601A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
MX2023006937A (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof.
Fredly et al. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Tan et al. Tumor-associated macrophages: a potential target for cancer therapy
Luongo et al. Possible therapeutic effects of ozone mixture on hypoxia in tumor development
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
BRPI0608840B8 (en) pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea, and its preparation process
HUP0303271A2 (en) Use of rapamycin for preparation of pharmaceutical composition suitable for cancer treatment
ES2617689T3 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
TW200740762A (en) Pyrazole compounds that modulate HSP90 activity
WO2023150601A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023245123A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
Senkevitch et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations
MX2009007777A (en) Combination therapy comprising romidepsin and i.a. bortezomib.
MX2024001193A (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof.
MX2023006938A (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof.
Nagai et al. Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
BRPI0409926A (en) saposin c-dops: an antitumor agent
IL197513A0 (en) Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same
WO2023250431A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
BRPI0511780A (en) oxoliplatin treatment and an egrf inhibitor
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2023000008A (en) Fgfr and mutation inhibitor thereof, and preparation method therefor and use thereof.
BR112021022966A2 (en) Method to reduce the size of the tumor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750382

Country of ref document: EP

Kind code of ref document: A2